Deutsche Bank AG Makes New $2.96 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

Deutsche Bank AG bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 63,729 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,964,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Rubric Capital Management LP bought a new position in Supernus Pharmaceuticals in the second quarter worth approximately $21,908,000. Assenagon Asset Management S.A. bought a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at about $27,428,000. Woodline Partners LP raised its holdings in shares of Supernus Pharmaceuticals by 63.5% in the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after acquiring an additional 490,835 shares in the last quarter. Rice Hall James & Associates LLC purchased a new stake in Supernus Pharmaceuticals in the second quarter worth about $22,800,000. Finally, Bank of New York Mellon Corp purchased a new stake in Supernus Pharmaceuticals in the second quarter worth about $17,553,000.

Analyst Upgrades and Downgrades

A number of research firms have commented on SUPN. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Cantor Fitzgerald lifted their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $62.83.

Supernus Pharmaceuticals Stock Performance

SUPN stock opened at $44.88 on Thursday. Supernus Pharmaceuticals, Inc. has a one year low of $42.45 and a one year high of $59.68. The firm has a market cap of $2.61 billion, a price-to-earnings ratio of -23.37, a PEG ratio of 0.84 and a beta of 0.56. The firm has a 50-day simple moving average of $46.83 and a two-hundred day simple moving average of $48.74.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The firm had revenue of $219.06 million during the quarter, compared to analysts’ expectations of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The firm’s quarterly revenue was up 32.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.40 EPS. As a group, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.